Torrent Pharmaceuticals Ltd (TORNTPHARM)
₹4,613.40
Mkt cap
₹1.75L Cr
P/E ratio
80.80
P/B
9.55
Div yield
0.82%
ROE
27.40%
ROCE
15.20%
EPS (TTM)
₹57.10
Book value
₹483
52W range
3,533–5,250
Sector
Healthcare
Price history
Previous close
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. [1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses. [2]
NSE TORNTPHARMBSE 500420
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−12.13% from high₹4,613
₹3,533+30.60% from low₹5,250
Current
₹4,613.40
Prev close
₹4,580.00
Day
+0.73%
Price performance
1D
+0.73%
1W
+1.97%
1M
−5.73%
3M
−5.31%
6M
+9.03%
1Y
+27.65%
YTD
+18.74%
Financials
Revenue, profit & margin
P/E ratio
80.8×
TORNTPHARM is 135% above the sector median of 34.4×
TORNTPHARM80.8×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 | 4,979 | |
| Expenses | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 | 3,313 | |
| Operating Profit | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 | 1,666 | |
| OPM % | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% | 33% | |
| Other Income | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 | -20 | |
| Interest | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 | 300 | |
| Depreciation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 | 609 | |
| Profit before tax | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 | 737 | |
| Tax % | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% | 28% | |
| Net Profit | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 | 534 | |
| EPS in Rs | 11.41 | 13.09 | 13.27 | 13.50 | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 | 18.76 | 10.76 | 16.72 | 14.04 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.66% · closed higher next day 32 of last 67
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 2 Feb '24◦ | 24 May '24◦ | 23 Jul '24◦ | 25 Oct '24◦ | 24 Jan '25◦ | 20 May '25◦ | 28 Jul '25◦ | 7 Nov '25◦ | 13 Feb '26◦ | 22 May '26◦ | 30 Jul '26◦ | 23 Oct '26◦ |
| Earnings day | +4.67% | +1.63% | +0.23% | −3.38% | +2.75% | +1.47% | +4.01% | +6.63% | +4.50% | +1.93% | +5.15% | +0.57% |
| +1 day | +3.37% | +2.07% | −1.70% | −6.33% | +2.04% | −0.91% | +2.97% | +6.87% | +4.42% | −0.76% | +3.65% | +2.22% |
| +5 days | +3.72% | +2.50% | +1.05% | −7.24% | −1.25% | −2.33% | −0.93% | +6.69% | +5.63% | −3.75% | +1.07% | — |
| +15 days | +3.90% | +10.50% | +6.69% | −9.64% | −7.22% | −1.10% | +1.13% | +4.38% | +8.58% | −0.43% | +0.50% | — |
| +30 days | −0.96% | +12.38% | +9.68% | −3.06% | −5.46% | +3.33% | −1.08% | +6.59% | −2.23% | +8.47% | +1.92% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 9 Per Share | 9.00 | 29 May '26 | 29 May '26 |
Shareholding
as of Sep 202660.78%Promoter
Promoters60.78%7.53
FIIs17.22%1.78
DIIs13.37%3.64
Public8.54%2.12
Government0.09%0.01
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts43
RECOct 2026TranscriptJul 2026TranscriptMay 2026RECMay 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025TranscriptMay 2025TranscriptJan 2025TranscriptOct 2024RECOct 2024TranscriptJul 2024TranscriptMay 2024TranscriptFeb 2024TranscriptAug 2023TranscriptMay 2023PPTSep 2022TranscriptMay 2021TranscriptFeb 2021TranscriptOct 2020
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 29 Oct - Q2 FY26-27 earnings call transcript posted on company website.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 23 Oct - Audio recording of 30 September 2026 financial results conference call uploaded.Board Meeting Outcome for Outcome Of Board Meeting Dated 23-Oct-26 23 Oct - Torrent Pharma approved Q2 and H1 FY2026-27 results on 23 October 2026; standalone and consolidated numbers reported.Results For Quarter And Half Year Ended 30-Sep-26 23 OctAnnouncement under Regulation 30 (LODR)-Change in Management 16 Oct - Amal Kelshikar resigned as Executive Director, effective close of business on 16 October 2026.